| scholarly article | Q13442814 |
| P50 | author | Peter D. Kwong | Q68690794 |
| Asim K Debnath | Q88490868 | ||
| Francesca Curreli | Q117751924 | ||
| P2093 | author name string | Hongtao Zhang | |
| Yongping Yang | |||
| Young Do Kwon | |||
| Daniel Scacalossi | |||
| P2860 | cites work | PHENIX: a comprehensive Python-based system for macromolecular structure solution | Q24654617 |
| Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity | Q24685633 | ||
| Processing of X-ray diffraction data collected in oscillation mode | Q26778468 | ||
| Structure-Based Design and Synthesis of an HIV-1 Entry Inhibitor Exploiting X-Ray and Thermodynamic Characterization | Q27678112 | ||
| Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops | Q27678226 | ||
| Structure-Based Design, Synthesis, and Characterization of Dual Hotspot Small-Molecule HIV-1 Entry Inhibitors | Q27678493 | ||
| Crystal Structures of HIV-1 gp120 Envelope Glycoprotein in Complex with NBD Analogues That Target the CD4-Binding Site | Q27681568 | ||
| Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody | Q27759364 | ||
| Coot: model-building tools for molecular graphics | Q27860505 | ||
| LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions | Q27861128 | ||
| Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype | Q28646874 | ||
| Antibody neutralization and escape by HIV-1 | Q29547345 | ||
| Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone | Q29547734 | ||
| Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication | Q39595771 | ||
| CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist. | Q39664933 | ||
| CD4 mimics targeting the mechanism of HIV entry | Q39772604 | ||
| Characterization and selection of HIV-1 subtype C isolates for use in vaccine development | Q40663802 | ||
| A CD4 mimic as an HIV entry inhibitor: pharmacokinetics. | Q42257833 | ||
| Small molecular CD4 mimics as HIV entry inhibitors | Q42725820 | ||
| Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions | Q44488145 | ||
| Effects of HIV Type 1 Envelope Glycoprotein Proteolytic Processing on Antigenicity | Q44614090 | ||
| Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure | Q44679186 | ||
| Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes | Q45052086 | ||
| HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus | Q45732337 | ||
| Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission | Q47878972 | ||
| Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. | Q53851964 | ||
| A soluble CD4 protein selectively inhibits HIV replication and syncytium formation | Q59081036 | ||
| Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen | Q68833722 | ||
| The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level | Q70213932 | ||
| Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies | Q29619015 | ||
| Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. | Q29619254 | ||
| Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection | Q29619510 | ||
| Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes | Q29619514 | ||
| Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. | Q29622903 | ||
| Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist. | Q30358736 | ||
| A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12. | Q31143293 | ||
| N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion | Q33208281 | ||
| Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state | Q33426352 | ||
| CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies | Q33743734 | ||
| High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates | Q33760671 | ||
| Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41. | Q33864690 | ||
| Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines | Q33911935 | ||
| Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds | Q33964006 | ||
| Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents | Q34592841 | ||
| Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening | Q34626673 | ||
| Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection | Q34806513 | ||
| HIV-1 cell entry and advances in viral entry inhibitor therapy | Q35071444 | ||
| Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa | Q35140032 | ||
| Isolation of CD4-independent primary human immunodeficiency virus type 1 isolates that are syncytium inducing and acutely cytopathic for CD8+ lymphocytes | Q35543127 | ||
| Enfuvirtide: A Novel Agent for the Treatment of HIV-1 Infection | Q35547218 | ||
| Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding | Q35845976 | ||
| A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding | Q35978823 | ||
| Design, synthesis, and antiviral activity of entry inhibitors that target the CD4-binding site of HIV-1. | Q36022790 | ||
| Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. | Q36793180 | ||
| Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. | Q36824891 | ||
| Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. | Q37002237 | ||
| Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155. | Q37010292 | ||
| Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India | Q37179996 | ||
| Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1 | Q37256644 | ||
| Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins | Q37415987 | ||
| Small molecule HIV entry inhibitors: Part II. Attachment and fusion inhibitors: 2004-2010. | Q37845842 | ||
| CD4 mimics as HIV entry inhibitors: lead optimization studies of the aromatic substituents. | Q39174717 | ||
| HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug. | Q39344552 | ||
| Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding | Q39485924 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 5478-5491 | |
| P577 | publication date | 2014-07-07 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Binding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-ray structure and resistance study | |
| P478 | volume | 58 |
| Q37593189 | Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds |
| Q36878885 | Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds |
| Q36125032 | Computational Evaluation of HIV-1 gp120 Conformations of Soluble Trimeric gp140 Structures as Targets for de Novo Docking of First- and Second-Generation Small-Molecule CD4 Mimics |
| Q39041742 | Computational identification of novel entry inhibitor scaffolds mimicking primary receptor CD4 of HIV-1 gp120. |
| Q36643050 | Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41 |
| Q37703084 | Driving HIV-1 into a Vulnerable Corner by Taking Advantage of Viral Adaptation and Evolution |
| Q41870119 | Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action |
| Q92619786 | In Silico Identification of Novel Aromatic Compounds as Potential HIV-1 Entry Inhibitors Mimicking Cellular Receptor CD4 |
| Q35835515 | Peptide Triazole Inactivators of HIV-1 Utilize a Conserved Two-Cavity Binding Site at the Junction of the Inner and Outer Domains of Env gp120. |
| Q89592396 | Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation |
| Q39079796 | Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015). |
| Q47714916 | Specific Non-Covalent Interactions Determine Optimal Structure of a Buried Ligand Moiety: QM/MM and Pure QM Modeling of Complexes of the Small-Molecule CD4 Mimetics and HIV1 Gp120. |
| Q92482128 | Strain-Dependent Activation and Inhibition of Human Immunodeficiency Virus Entry by a Specific PF-68742 Stereoisomer |
| Q36364955 | Structure-Based Design of a Small Molecule CD4-Antagonist with Broad Spectrum Anti-HIV-1 Activity |
| Q59359981 | Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120 |
| Q59351886 | Synthesis, Antiviral Activity, and Structure-Activity Relationship of 1,3-Benzodioxolyl Pyrrole-Based Entry Inhibitors Targeting the Phe43 Cavity in HIV-1 gp120 |
| Q38816992 | Synthesis, antiviral activity and resistance of a novel small molecule HIV-1 entry inhibitor |
| Q59350387 | Virtual Screening, Biological Evaluation, and 3D-QSAR Studies of New HIV-1 Entry Inhibitors That Function via the CD4 Primary Receptor |
Search more.